Locations:
Search IconSearch

Add These Presentations to Your AAN Meeting Itinerary

Cleveland Clinic experts address PD, AD, MS and more

17-NEU-712-AANAM-650×450

This year’s American Academy of Neurology Annual Meeting is approaching fast. If you’re going to Boston for the late-April meeting, make room in your itinerary for the following selected key presentations by Cleveland Clinic experts.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

If you can’t make it to the conference, check back here on Consult QD or on Cleveland Clinic’s social media channels for medical professionals (@CleClinicMD or Facebook.com/CMEClevelandClinic) for reports on most presentations below soon after they take place.

Parkinson’s Disease Update: Part I

First half of a two-hour CME event on Parkinson’s disease

Presented by Hubert Fernandez, MD, Director, Cleveland Clinic Center for Neurological Restoration

Sat., April 22, 8-9 a.m.

CSF Total Tau in Alzheimer’s Disease

Poster P1.093: “Elevated cerebrospinal fluid total Tau level reflects predominant cortical atrophy in Alzheimer’s disease”

Presented by Jagan Pillai, MD, PhD, Cleveland Clinic Lou Ruvo Center for Brain Health

Sun., April 23, 8:30 a.m.-5:30 p.m.

Stem Cells in Neurological Diseases

“The Devilish Details, Challenges, and Uncertainties,” a talk in the “Section Topic Controversies” session on stem cells for treatment of neurological diseases

Presented by Jeffrey Cohen, MD, Director, Cleveland Clinic Mellen Center for MS Treatment and Research

Tue., April 25, 4:00-4:30 p.m.

RADIANCE 2-Year Blinded Extension Results

Platform presentation S24.008: “Efficacy and safety of ozanimod: Results from the 2-year blinded extension of the RADIANCE phase 2 trial in relapsing multiple sclerosis”

Presented by Jeffrey Cohen, MD, Director, Cleveland Clinic Mellen Center for MS Treatment and Research

Tue., April 25, 4:54-5:06 p.m.

AIM-TD Trial of Deutetrabenazine for Tardive Dyskinesia

Platform presentation S56.004: “Addressing involuntary movements in tardive dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change with deutetrabenazine treatment in moderate to severe tardive dyskinesia”

Advertisement

Presented by Hubert Fernandez, MD, Director, Cleveland Clinic Center for Neurological Restoration

Fri., April 28, 4:06-4:18 p.m.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad